Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $25,040.00 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 1,000 shares of the stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $25.04, for a total transaction of $25,040.00. Following the sale, the chief financial officer now directly owns 13,000 shares of the company’s stock, valued at $325,520. The trade was a 7.14 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Benjamin Hohl also recently made the following trade(s):

• On Monday, December 30th, Benjamin Hohl sold 900 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.51, for a total transaction of $20,259.00.
• On Friday, December 27th, Benjamin Hohl sold 3,350 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.15, for a total value of $74,202.50.
• On Wednesday, November 27th, Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $24.89, for a total value of $130,672.50.
• On Monday, October 28th, Benjamin Hohl sold 6,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $28.56, for a total value of $178,500.00.
• On Friday, October 18th, Benjamin Hohl sold 814 shares of Enliven Therapeutics stock. The stock was sold at an average price of $30.00, for a total value of $24,420.00.

Enliven Therapeutics Trading Up 1.2 %

Shares of NASDAQ ELVN opened at $24.15 on Friday. The company has a 50 day simple moving average of $24.66 and a two-hundred day simple moving average of $24.39. The stock has a market cap of $1.18 billion, a price-to-earnings ratio of -12.71 and a beta of 1.04. Enliven Therapeutics, Inc. has a 12 month low of $10.90 and a 12 month high of $30.03.

Analysts Set New Price Targets

A number of research firms recently commented on ELVN. BTIG Research assumed coverage on shares of Enliven Therapeutics in a research note on Friday, December 13th. They issued a “buy” rating and a $42.00 target price for the company. Robert W. Baird boosted their price objective on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the company an “outperform” rating in a report on Friday, November 15th. Finally, HC Wainwright restated a “buy” rating and issued a $37.00 target price on shares of Enliven Therapeutics in a research note on Tuesday, October 1st. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $38.25.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Barclays PLC grew its position in Enliven Therapeutics by 295.8% during the 3rd quarter. Barclays PLC now owns 56,217 shares of the company’s stock worth $1,435,000 after purchasing an additional 42,012 shares during the period. First Turn Management LLC boosted its stake in shares of Enliven Therapeutics by 29.5% in the third quarter. First Turn Management LLC now owns 535,092 shares of the company’s stock worth $13,666,000 after buying an additional 121,849 shares during the last quarter. Geode Capital Management LLC grew its holdings in Enliven Therapeutics by 9.9% during the third quarter. Geode Capital Management LLC now owns 750,208 shares of the company’s stock worth $19,164,000 after acquiring an additional 67,813 shares during the period. Ally Bridge Group NY LLC purchased a new position in Enliven Therapeutics during the third quarter valued at approximately $5,998,000. Finally, Patient Square Capital LP purchased a new stake in Enliven Therapeutics in the 3rd quarter worth approximately $2,313,000. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.